A remarkable case of recovery: Sacubitril/valsartan effectively
prevents hospital readmission in a patient with HF following AMI
05 May 2020
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.
Related MIMS Drugs